Up to 1,500 GP practices and drive-through sites will be open every day from 8am to 8pm to carry out the vaccination efforts according to the Daily Telegraph. Each centre will give out at least 1,000 vaccines per week.
In total, at least one million jabs will be dispensed weekly according to the plans.
Medicine and nursing students, as well as retired healthcare professionals, will be taking part in the vaccination drive helping deliver jabs as rapidly as they can be administered.
Pharmaceutical giant Pfizer has announced its vital coronavirus vaccine is more than 90 percent effective following trials.
Prime Minister Boris Johnson said he expects to have 10million doses of the vaccine by the end of the year if it is authorised by regulators.
On Monday Dr Albert Bourla, Pfizer chairman and CEO said: “Today is a great day for science and humanity.
“The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent Covid-19.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”
Pfizer is working with BioNTech in the development of the jab and is one of two main candidates alongside Oxford University and AstraZeneca.
“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavour. We could not have come this far without the tremendous commitment of everyone involved.”
A Government spokesperson said the findings from Pfizer/BioNTech are very promising, adding 40 million doses of their vaccine had been ordered.
However, the spokesperson warned that no guarantees could be taken yet.
Speaking to the Daily Telegraph they said: “We will know whether the vaccine meets our robust standards of safety and effectiveness once their safety data has been published, and only then can the medicines regulator consider whether it can be made available to the public.
